Skip to main content
[Preprint]. 2021 May 3:2021.05.03.442455. [Version 1] doi: 10.1101/2021.05.03.442455

Figure 2. SARS-CoV-2 specific T-cell responses in vaccinated cohorts.

Figure 2.

A. ELISpot results for convalescent patients compared to fully vaccinated donors (V2) (Kruskall Wallis with Dunn’s multiple comparison test where *p=0.0311 and *****p<0.00001). B. ELISpot results assessed prior to vaccination (V0), post first vaccination dose (V1), and post second vaccination dose (V2) (Kruskal-Wallis with Dunn’s multiple comparisons test where, ****p<0.0001, **p=0.018). Differences between convalescent results versus V0 where ****p<0.0001, *p=0.0219 (Mann-Whitney test). C. Spike subunit 1 (S1) and subunit 2 (S2) structures shown independently (left) and as a representative monomer of the in situ trimer (right, two additional monomers shown in gray). D. Schematic of novel whole blood IFNγ release assay (hereon referred to as “whole blood assay”). E. Heatmap of IFNγ release (IU/ml) to S1 and S2 subdomains in the whole blood assay from donors for which all results were available. The highest response to either S1 or S2 is indicated in Max response column. Paired serums for anti-spike IgG/IgA/IgM reported as positive (black) or negative (white). F. Composite whole blood assay IFNγ responses (Kruskal-Wallis test with Dunn’s multiple comparisons test where S1: *p=0.0461, **p=0.0028 and for S2: **p=0.034 and ****p<0.0001). Dotted line indicates a positive threshold of 0.3 IU/ml. Median shown for A, B, and F. SP= Spike pool.